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Aims Various beta-blockers with distinct pharmacological proﬁles are approved in heart failure, yet they remain underused
and underdosed. Although potentially of major public health importance, whether one agent is superior in terms of
tolerability and optimal dosing has not been investigated. The aim of this study was therefore to compare the toler-
ability and clinical effects of two proven beta-blockers in elderly patients with heart failure.
Methods
and results
We performed a double-blind superiority trial of bisoprolol vs. carvedilol in 883 elderly heart failure patients with
reduced or preserved left ventricular ejection fraction in 41 European centres. The primary endpoint was tolerability,
deﬁned as reaching and maintaining guideline-recommended target doses after 12 weeks treatment. Adverse events
and clinical parameters of patient status were secondary endpoints. None of the beta-blockers was superior with
regards to tolerability: 24% [95% conﬁdence interval (CI) 20–28] of patients in the bisoprolol arm and 25% (95%
CI 21–29) of patients in the carvedilol arm achieved the primary endpoint (P ¼ 0.64). The use of bisoprolol resulted
in greater reduction of heart rate (adjusted mean difference 2.1 b.p.m., 95% CI 0.5–3.6, P ¼ 0.008) and more, dose-
limiting, bradycardic adverse events (16 vs. 11%; P ¼ 0.02). The use of carvedilol led to a reduction of forced expira-
tory volume (adjusted mean difference 50 mL, 95% CI 4–95, P ¼ 0.03) and more, non-dose-limiting, pulmonary
adverse events (10 vs. 4%; P , 0.001).
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doi:10.1093/eurjhf/hfr020Conclusion Overall tolerability to target doses was comparable. The pattern of intolerance, however, was different: bradycardia
occurred more often in the bisoprolol group, whereas pulmonary adverse events occurred more often in the car-
vedilol group.
This study is registered with controlled-trials.com, number ISRCTN34827306.
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Introduction
Chronic heart failure is a growing epidemic associated with high
mortality, morbidity, and quality of life (QoL) impairment and is
a substantial burden on health systems.
1 Three key trials have ran-
domized nearly 9000 patients with systolic heart failure to beta-
blocker (bisoprolol, carvedilol, or metoprolol succinate controlled
release) or placebo and demonstrated a consistent 30% reduction
in mortality and a 40% reduction in hospitalizations.
2–4 Neverthe-
less, recent large international surveys have shown that only 20–
40% of heart failure patients are taking beta-blockers and the
mean dose is half the recommended target.
5,6
The underuse and underdosing of beta-blockers may reﬂect a
reluctance to change practice stemming from their long-standing
contraindication in heart failure. Conversely, it may reﬂect a true
lackoftolerabilityofbeta-blockersinpatientswhoaretypically rela-
tivelyold,haveco-morbidities,and are takingarangeofotherdrugs.
It is noteworthy that many previous beta-blocker trials included
heart failure patients who were younger (mean age 61–64) than
those encountered in routine practice (mean age 71–75).
2–4,7,8
Class effects may not be uniform and tolerability may differ
between the commonly used beta-blockers, reﬂecting their distinct
pharmacologicalproﬁlessuchasselectivityfortheb1-adrenoceptor
subtype (bisoprolol) or vasodilatory activity (carvedilol). However,
differences in tolerability have not been systematically studied. If
one proven beta-blocker were better tolerated than another it
could be of considerable public health importance. Results of the
Carvedilol Or Metoprolol European Trial (COMET), suggested
that overall tolerability of carvedilol vs. metoprolol tartrate does
not differ,
8 but it has been suggested that this interpretation is pro-
blematicbecausedoseswerenotequivalent.
9ThesecondCarvedilol
Open-Label Assessment found good tolerability for carvedilol in
olderheart failure patients,
10 but no previousdouble-blind random-
ized trial had tolerability as the primary endpoint.
Beta-blocker therapy in patients with preserved left ventricular
ejection fraction (LVEF) is associated with an improvement in
echocardiographic parameters
11 and international guidelines
provide an expert-based recommendation of heart rate lowering
using beta-blockers in these patients
12 despite a lack of proven
reduction in mortality.
We therefore designed the Cardiac Insufﬁciency Bisoprolol
Study in Elderly (CIBIS-ELD) to investigate the tolerability of two
of the most widely used beta-blockers in elderly heart failure
patients with impaired and preserved LVEF. This is the ﬁrst ran-
domized, double-blind trial to have as its primary endpoint the tol-
erability of bisoprolol vs. carvedilol when used at their
guideline-recommended target doses.
Methods
Trial design and patients
We undertook this investigator-initiated, randomized, double-blind,
parallel-group trial in 21 centres in Germany, 1 in Montenegro, 15 in
Serbia, and 4 in Slovenia. The CIBIS-ELD protocol was approved by
all relevant federal institutes for drugs and medical devices as well as
by national and local ethics committees. Patients provided written
informed consent and the trial conforms to the principles outlined in
the Declaration of Helsinki. Details of the CIBIS-ELD trial design
have been published elsewhere.
13 This study is registered with
controlled-trials.com, number ISRCTN34827306.
Patients were recruited between April 2005 and April 2008
(Figure 1). Eligible patients were 65 years or older with symptomatic
chronic heart failure consistent with New York Heart Association
(NYHA) functional class ≥II at time of enrolment or with an
LVEF ≤ 45%. At baseline, participants had to be beta-blocker naı ¨ve
or on ≤25% of the guideline-recommended target or equivalent
dose.
14 Patients who had been on suboptimal doses previously were
included to investigate titration success following pretreatment.
Patients had to be clinically stable and on stable medication for 2
weeks prior to randomization.
Major exclusion criteria were: known contraindications to beta-
blocker treatment, such as hypotension with a resting systolic blood
pressure ,90 mmHg, severe pulmonary disease or severe asthma,
heart rate ,55 b.p.m. prior to commencement of therapy, second
or third degree sinoatrial block (without pacemaker), and known
sick sinus syndrome.
Procedures
Patients were recruited through primary care physicians, and sec-
ondary and tertiary care hospitals. Upon enrolment, they were
randomly assigned to either bisoprolol or carvedilol. For each
centre, a random sequence of permuted blocks of variable
length was generated by the Clinical Trial Centre Leipzig. Patients,
investigators, and study personnel were blinded to treatment
assignment for the duration of the trial.
During the initial titration phase of the study, patients were seen
at fortnightly intervals. According to the titration scheme [based
on the 2005 European Society of Cardiology (ESC) guidelines],
14
the dose was scheduled to double at every visit to reach the
target dose of 10 mg bisoprolol once daily or 25 mg carvedilol
twice daily within 6 weeks (50 mg twice daily within 8 weeks for
patients .85 kg). Investigators were free to delay titration or
reduce the dose if clinically indicated. The titration phase was fol-
lowed by a maintenance period lasting 4 weeks and the ﬁnal visit
was at 10 weeks (12 weeks for patients .85 kg).
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The primary endpoint of tolerability was deﬁned as reaching the
target dose through the process of fortnightly doubling with no
more than one delayed increase and with the target dose main-
tained for at least 10 days. Titration failure was deﬁned as failure
to up-titrate more than once or as down-titration after receiving
the target dose level. Predeﬁned secondary endpoints were the
percentage of target dose achieved at the end of the study, and
the dose achieved prior to ﬁrst titration failure. Occurrences of
adverse events were recorded and their association with dose
adjustment was assessed by odds ratios. For titration failures
with no simultaneous adverse event, we implemented a blinded
endpoint committee consisting of experts with sound clinical
experience in heart failure therapy and research who evaluated
the circumstances of titration failure based on data from all visits
and additional investigator comments. Multiple reasons could be
speciﬁed by the endpoint committee (Appendix).
Predeﬁned clinical secondary endpoints were: NYHA functional
class, heart rate, blood pressure (measured prior to dose titration
at each visit) and LVEF, assessment of diastolic function, 6 min walk
distance, 1 s forced expiratory volume (FEV1) and the physical and
psychosocial component scores on the short-form QoL health
survey (SF36) at the end of the study, adjusted for baseline.
Statistical analysis
All analyses were carried out by intention to treat, including all
patients who received the ﬁrst dose of allocated study medication.
Patients who died or prematurely stopped treatment were judged
not to have fulﬁlled the conditions for the primary endpoint. A sen-
sitivity analysis was performed counting deaths as drop-outs. The
primarynullhypothesisthatequalpercentagesofpatientswouldtol-
erate the target doses of the two agents was tested against the two-
sidedalternativebyFisher’sexacttest.Thiswasdesignedtodiscover
the superiority of one beta-blocker assuming 60 vs. 50% tolerability
Figure 1 Participant ﬂow through the study. Target dose based on the 2005 European Society of Cardiology guidelines.
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Table 1 Baseline characteristics
All patients Bisoprolol Carvedilol
(n 5 876) (n 5 431) (n 5 445)
Women, no. (%) 329 (38) 167 (39) 162 (36)
Age, mean (SD), years 72.8 (5.5) 72.9 (5.6) 72.7 (5.5)
NYHA class
I 34 (4) 15 (4) 19 (4)
II 575 (66) 272 (63) 303 (68)
III 258 (30) 139 (32) 119 (27)
IV 9 (1) 5 (1) 4 (1)
Hospitalization for heart failure during the past 12 months, no. (%) 314 (36) 143 (33) 171 (38)
Heart rate on ECG, mean (SD), b.p.m. 73 (14) 74 (15) 73 (14)
Blood pressure, mean (SD), mmHg
Systolic 137 (21) 137 (21) 137 (22)
Diastolic 80 (12) 80 (12) 80 (12)
LVEF, mean (SD),% 42 (14) 42 (14) 42 (13)
LVEF . 45%, no. (%) 250 (29) 123 (29) 127 (29)
6 min walk distance, mean (SD), m 322 (110) 319 (103) 325 (116)
NT-pro-BNP, median (IQR), pg/mL 609 (255–1614) 596 (236–1699) 630 (284–1587)
Haemoglobin, mean (SD), g/dL 13.7 (1.6) 13.7 (1.6) 13.7 (1.6)
FEV1, mean (SD), mL 2192 (675) 2185 (712) 2197 (638)
FEV1, predicted for age and sex (%), mL 90.8 (23.9) 90.4 (24.8) 91.2 (23.1)
Peripheral oedema, no. (%) 183 (21) 88 (20) 95 (21)
Body mass index, mean (SD), kg/m
2 27.7 (4.9) 28.0 (5.0) 27.6 (4.7)
Medical history, no. (%)
Current smoker 76 (9) 41 (10) 35 (8)
Myocardial infarction 347 (40) 163 (38) 184 (41)
PCI and/or CABG 196 (22) 90 (21) 106 (24)
Pacemaker and/or ICD 56 (6) 23 (5) 33 (7)
Co-morbidities
a
Hypertension 724 (83) 353 (82) 371 (84)
Diabetes mellitus 223 (26) 107 (25) 116 (26)
Hyperlipidaemia 548 (63) 261 (61) 287 (65)
Peripheral vascular disease or stroke 121 (14) 59 (14) 62 (14)
Atrial ﬁbrillation 164 (19) 83 (19) 81 (18)
COPD 65 (7) 28 (7) 37 (8)
Renal dysfunction [GFR , 60] 338 (39) 165 (38) 173 (39)
Anaemia [male: Hb , 13 g/dL; female: Hb , 12 g/dL] 181 (21) 86 (20) 95 (21)
Depression 73 (8) 34 (8) 39 (9)
Cardiovascular medication, no. (%)
Beta-blocker
None 349 (40) 175 (41) 174 (39)
12.5% of target dose equivalent 149 (17) 75 (17) 74 (17)
25% of target dose equivalent 378 (43) 181 (42) 197 (44)
ACE inhibitor and/or ARB 741 (85) 374 (87) 367 (83)
Aldosterone receptor antagonist 275 (31) 145 (34) 130 (29)
Diuretic 649 (74) 323 (75) 326 (73)
Cardiac glycoside 129 (15) 64 (15) 65 (15)
Calcium channel blocker 143 (16) 80 (19) 63 (14)
Nitrate 277 (32) 131 (30) 146 (33)
Antiarrhythmic 95 (11) 48 (11) 47 (11)
Statin 342 (39) 159 (37) 183 (41)
Antiplatelet 582 (66) 287 (66) 295 (66)
Anticoagulant 220 (25) 102 (24) 118 (26)
Continued
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Mann–Whitney U test. Percentages of patients achieving the target
dosefreeoftitrationfailurearepresentedasKaplan–Meieranalyses.
Prespeciﬁed baseline variables were examined for being predictors
for achievement of target dose by multiple logistic regression.
Only 26 patients (bisoprolol n ¼ 11, carvedilol n ¼ 15) reached
the higher dose level applicable to patients .85 kg; therefore data
for this group were not analysed separately.
Changes in clinical endpoints are presented as mean differences
and their signiﬁcance assessed within each treatment group by
paired t-test. Comparison across groups was carried out by analy-
sis of covariance (ANCOVA) with the follow-up measurement as
dependent variable, the randomized agent as factor, and the base-
line measurement as covariate (or as categorical co-factor in case
of NYHA class). Patients with a pacemaker were excluded from
the analysis of change in heart rate. Percentages of patients who
had an adverse event were compared using Fisher’s exact test.
Analyses were performed using SPSS Version 15 (SPSS Inc.,
Chicago, IL, USA).
Sample size
The study was designed to detect a 10% difference between
arms with a power of 80–90% on the assumption that at
least 50% of all patients would meet the criterion for tolerabil-
ity. We therefore needed to recruit 760–1040 patients at a sig-
niﬁcance level of 5%. In April 2008, we had enrolled 883
patients, leading to a power of 85%. For the detection of 25
vs. 35% tolerability, power was 90%. Since the primary endpoint
was deﬁned for all patients, no adjustment for drop-outs was
necessary.
Results
A total of 883 patients were randomized (Germany n ¼ 300, Mon-
tenegro n ¼ 18, Serbia n ¼ 535, and Slovenia n ¼ 30), 876 of
whom received the ﬁrst dose of the study medication. One
patient was erroneously excluded from further trial participation
by an investigator; no patient was lost to follow-up (Figure 1). Base-
line characteristics are shown in Table 1 and there were no imbal-
ances between treatment groups.
Primary endpoint
None of the beta-blockers was superior with regards to tolerabil-
ity according to the primary endpoint of reaching the respective
target doses when following the recommended titration scheme
(Table 2). This result remained the same when adjusting for treat-
ment effect covariates (Figure 2). Kaplan–Meier estimates show
that the percentage of patients reaching the ascending dose
levels in line with the titration scheme did not differ between
groups (Figure 3). Overall, 31% of patients reached the full, and
55% tolerated at least half of the target doses (Table 2). The
mean daily dose reached at follow-up was 5.0 mg for bisoprolol
and 23.9 mg for carvedilol in patients ≤85 kg (47.7 mg in patients
.85 kg). Factors associated with reaching the primary endpoint
are shown in Figure 2.
...............................................................................................................................................................................
Table 1 Continued
All patients Bisoprolol Carvedilol
(n 5 876) (n 5 431) (n 5 445)
QoL, mean (SD)
SF-36 physical component score 38.2 (9.5) 37.9 (9.3) 38.5 (9.7)
SF-36 psychosocial component score 45.4 (12.1) 44.5 (11.8) 46.2 (12.4)
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; GFR, glomerular ﬁltration rate; Hb, haemoglobin; FEV1, forced
expiratory volume in the ﬁrst second; ICD, implantable cardioverter deﬁbrillator; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro b-type natriuretic peptide;
NYHA, New York Heart Association; PCI, percutaneous coronary intervention.
aCo-morbidities determined during medical examination or as deﬁned in square brackets.
..............................
................................................................................









102 (24) 112 (25) 0.64
95% CI for rate 20–28 21–29
Dose level at follow-up,
no. (%)
0.58
0 (study medication stopped
before follow-up)
46 (11) 51 (11)
12.5% (1.25 mg bisoprolol or
3.125 mg carvedilol)
47 (11) 45 (10)
25% (2.5 mg bisoprolol or
6.25 mg carvedilol)
108 (25) 97 (22)
50% (5 mg bisoprolol or
12.5 mg carvedilol)
98 (23) 110 (25)
100% (10 mg bisoprolol or
1–2×25 mg carvedilol)
132 (31) 142 (32)
aPrimary endpoint achieved: the patient was up-titrated to the
guideline-recommended target dose and remained on this dose level until
follow-up. The dose was never reduced but delay of titration was allowed.
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In total, 668 patients (75.7%) did not reach the primary endpoint
and experienced at least one titration failure. While there was
no overall difference between the two groups, bradycardia
(deﬁned as heart rate ,55 b.p.m. or a heart rate below
60 b.p.m. plus a decrease of more than 15%) was the most
common reason for titration failure and occurred more often in
the bisoprolol group (Table 3). These episodes were associated
with more dose reductions (P ¼ 0.003) as well as a lower likeli-
hood of achieving the target dose (P , 0.001).
Pulmonary adverse events, which included a change in FEV1
of ≥20%, or clinical symptoms such as breathing difﬁculty,
obstructive ventilatory disorders, and bronchospasm occurred
more often in the carvedilol group than among patients taking
bisoprolol. However, pulmonary adverse events were not dose-
limiting nor led to withdrawal of carvedilol. Anaemia occurred
more often in patients taking carvedilol (Table 3). A decrease
in mean haemoglobin was seen in the carvedilol group
(Table 4), and this effect was more pronounced in patients
who were beta-blocker naı ¨ve at baseline (interaction term:
P , 0.01). Other adverse events with no difference between
groups were worsening heart failure, hypotension, hospital
admission, and mortality (Table 3).
Potential reasons for down-titration, slowed titration, or dis-
continuation deﬁned by the blinded endpoint committee
included undesirable reduction in heart rate ≤60 b.p.m. (n ¼
70, 8.0%); undesirable reduction in blood pressure
≤100 mmHg systolic/≤60 mmHg diastolic (n ¼ 21, 2.4%), logisti-
cal reasons (n ¼ 14, 1.6%), and patient refusing the medication
for unknown reasons (n ¼ 31, 3.5%). Patients in the bisoprolol
group were more likely to be affected by an undesirable
Figure 2 Predictors of tolerability. Filled diamonds indicate factors signiﬁcantly related to outcome.
Figure 3 Kaplan–Meier estimate showing that the percentage
of patients reaching the ascending dose levels in line with the
titration scheme did not differ between groups. White circles
indicate bisoprolol and black circles indicate carvedilol.
Titration to target dose of bisoprolol vs. carvedilol 675reduction in heart rate [n ¼ 45 (12%) vs. carvedilol n ¼ 25 (6%);
P ¼ 0.01]. There were no differences between bisoprolol and
carvedilol with regards to the other reasons for down-titration,
slowed titration, or discontinuation.
Change in New York Heart Association
class, left ventricular ejection fraction,
6 min walk distance, quality of life, heart
rate, and 1 s forced expiratory volume
New York Heart Association functional class, LVEF, 6 min walk dis-
tance and QoL improved to the same extent over the period of
the study in each treatment group; blood pressure was lowered
equally. Heart rate decreased in both groups from baseline to
follow-up, but the reduction was greater in the bisoprolol group.
Mean FEV1 decreased in the carvedilol group whereas it remained
stable in the bisoprolol group (Table 4).
Discussion
In this ﬁrst head-to-head comparison trial of two approved beta-
blockers in elderly heart failure patients, we found no superiority
of bisoprolol vs. carvedilol or vice versa with regards to tolerability
to target doses, but the reasons for not reaching the primary end-
point and the clinical reaction to the beta-blockers differed.
........................................................
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Table 3 Adverse events and relationship to target dose
Number of adverse events
Bisoprolol Carvedilol P-value
Any adverse event, no. (%) 281 (65) 284 (64) 0.67
Death 9 (2) 4 (1) 0.17
Hospitalization 13 (3) 14 (3) 1.00
Worsening heart failure 95 (22) 94 (21) 0.74
Bradycardia 70 (16) 47 (11) 0.02
New AV block 46 (11) 39 (9) 0.36
Hypotension 37 (9) 44 (10) 0.56
Fatigue/ drowsiness 46 (11) 23 (5) 0.003
Vertigo 32 (7) 32 (7) 1.00
Pulmonary 16 (4) 44 (10) 0.01
Renal dysfunction 36 (8) 29 (7) 0.31
Anaemia 29 (7) 52 (12) 0.01
Hyperuricaemia 20 (5) 20 (5) 1.00
Hyperlipidaemia 22 (5) 23 (5) 1.00
Odds ratio for relationship of BB titration with AE
Bisoprolol Carvedilol
Any titration failure Dose reduction Any titration failure Dose reduction
Any adverse event 2.10** 2.88*** 2.08** 1.04
Death †
Hospitalization 0.79 6.62*** 3.58 3.75*
Worsening heart failure 1.19 1.36 1.53 1.52
Bradycardia 1.60 3.04*** 4.35** 0.91
New AV block 1.75 1.09 2.49 0.92
Hypotension 1.66 0.87 2.23 1.28
Fatigue/ drowsiness 12.75*** 3.90*** 2.93 4.58***
Vertigo 1.38 2.30* 2.03 3.15**
Pulmonary 1.08 1.26 1.23 0.66
Renal dysfunction 1.04 0.64 0.83 0.29*
Anaemia 0.77 0.42 1.32 0.09***
Hyperuricaemia 2.31 0.91 0.80 0.46
Hyperlipidaemia 1.13 0.26 0.75 0.39
Anaemia ¼ male: Hb , 13 g/dL; female: Hb , 12 g/dL; bradycardia ≤ 55 b.p.m. or ,60 b.p.m. with 15% change from previous visit; hyperlipidaemia ≥ 260 mg/dL or increase by
30%; hyperuricaemia ≥ 6.5 mg/dL or increase by 30%; hypotension ≤ 90 mmHg systolic/,60 mmHg diastolic; pulmonary, clinical assessment of breathing difﬁculty; obstructive
ventilatory disorders or bronchospasm or drop of FEV1 by ≥20%; renal dysfunction, GFR , 60.
*P , 0.05; **P , 0.01; ***P , 0.001.
†, odds ratio not applicable.
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rate
Recent publications have conﬁrmed heart rate reduction as an
important target in the treatment of heart failure.
15,16 The selective
b1-adrenoceptor-blocker bisoprolol was associated with a larger
heart rate reduction and more bradycardic adverse events than
the non-selective a1-, b1-, and b2-adrenoceptor-blocker carvedilol.
Sole alpha-blockade is known to increase heart rate and the com-
bination of alpha- and beta-blockade in one molecule appears to
weaken its heart rate lowering effect.
17 Although this difference
in selectivity may explain our results, CIBIS-ELD is the ﬁrst com-
parison trial to provide evidence of its clinical relevance in heart
failure patients. In multivariate analysis, higher baseline heart rate
predicted better tolerability of target doses, regardless of treat-
ment group. Of note, the baseline mean heart rate was relatively
low in this study (73 b.p.m.) when compared with other heart
failure trials such as CIBIS II (80 b.p.m.),
2 CIBIS III (79 b.p.m.),
18
and COMET (81 b.p.m.).
8 The lower baseline heart rate of patients
in this trial may explain at least in part why the mean daily dose
reached (bisoprolol: 5.0 mg; carvedilol: 23.9 mg for patients
≤85 kg; and 47.7 mg for patients .85 kg) was lower than that
observed, for example, in CIBIS III (mean bisoprolol dose
8.3 mg),
18 and in COMET (mean carvedilol dose 41.8 mg, com-




Beta-blockers are frequently not up-titrated or even withheld for
fear of bronchoconstriction.
In this trial carvedilol was associated with more pulmonary
adverse events than bisoprolol and with a reduction of FEV1,
which is in line with its pharmacodynamic properties. Incidence
of pulmonary adverse events was nonetheless moderate in both
groups. In contrast to pre-existing opinions, neither these
...............................................................................................................................................................................
Table 4 Clinical endpoints
Bisoprolol (B) Carvedilol (C) Difference B–C from ANCOVA
NYHA functional class (n ¼ 386) (n ¼ 396)
Mean change (95% CI) 20.29 (20.35 to 20.24) 20.25 (20.30 to 20.20) 20.01 (20.08 to +0.05)
P-value ,0.001 ,0.001 0.71
Heart rate on ECG
a, b.p.m. (n ¼ 367) (n ¼ 369)
Mean change (95% CI) 28.4 (29.8 to 27.0) 26.0 (27.2 to 24.7) 22.1 (23.6 to 20.5)
P-value ,0.001 ,0.001 0.008
Systolic blood pressure, mmHg (n ¼ 386) (n ¼ 396)
Mean change (95% CI) 29.3 (211.4 to 27.3) 29.5 (211.7 to 27.3) +0.6 (21.7 to +2.9)
P-value ,0.001 ,0.001 0.60
Diastolic blood pressure, mmHg (n ¼ 386) (n ¼ 396)
Mean change (95% CI) 24.7 (25.9 to 23.5) 24.2 (25.4 to 23.0) 20.3 (21.6 to +1.1)
P-value ,0.001 ,0.001 0.69
LVEF,% (n ¼ 383) (n ¼ 394)
Mean change (95% CI) +3.0 (+2.3 to +3.7) +2.7 (+2.0 to +3.4) +0.4 (20.5 to +1.4)
P-value ,0.001 ,0.001 0.36
6-min-walk distance, m (n ¼ 357) (n ¼ 358)
Mean change (95% CI) +19 (+11 to +26) +13 (+6t o+19) +5( 24t o+14)
P-value ,0.001 ,0.001 0.25
Haemoglobin, g/dL (n ¼ 358) (n ¼ 373)
Mean change (95% CI) –0.07 (20.20 to +0.06) 20.24 (20.37 to 20.11) +0.15 (20.02 to +0.32)
P-value 0.28 ,0.001 0.07
FEV1,m L ( n ¼ 349) (n ¼ 365)
Mean change (95% CI) +3( 232 to +39) 242 (273 to 211) +50 (+4t o+95)
P-value 0.86 0.007 0.03
SF-36 physical component score (n ¼ 289) (n ¼ 295)
Mean change (95% CI) +2.4 (+1.6 to +3.3) +2.0 (+1.1 to +2.9) +0.4 (20.7 to +1.5)
P-value ,0.001 ,0.001 0.49
SF-36 psychosocial component score (n ¼ 289) (n ¼ 295)
Mean change (95% CI) +3.5 (+2.4 to +4.7) +2.6 (+1.5 to +3.7) +0.4 (21.0 to +1.7)
P-value ,0.001 ,0.001 0.61
CI, conﬁdence interval; FEV1, forced expiratory volume in the ﬁrst second; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
aExcluding patients with
pacemaker.
Titration to target dose of bisoprolol vs. carvedilol 677adverse events nor the reduction in FEV1 with carvedilol were a
signiﬁcant limitation for up-titration. Furthermore, the presence
of chronic obstructive pulmonary disease (COPD), which was
the most powerful independent predictor of beta-blocker underu-
tilization in the EuroHeart Failure Survey,
6 was not predictive of
less ability to titrate dose upwards in our trial. In a study that
looked speciﬁcally at heart failure patients with COPD receiving
bisoprolol or placebo, bisoprolol was associated with a 5%
reduction in FEV1.
19 However, this did not cause pulmonary symp-
toms or impair QoL.
Tolerability of beta-blocker therapy in
CIBIS-ELD
Titration scheme
The observation that only 31% of patients reached their
target dose contrasts with ﬁndings from previous trials, in which
42–87% of patients reached the recommended target
doses.
2–4,8,18,20 However, these previous trials enrolled younger
patients (60–63 years), allowed a longer duration of titration
(10–16 weeks and longer if clinically indicated), and also allowed
more than one delay in titration, and/or intermediate dose steps
(for bisoprolol 3.75 and 7.5 mg) instead of a doubling of the
dose every fortnight as recommended by the 2005 ESC guidelines.
The new 2008 ESC guidelines adopt the titration schemes of these
larger beta-blocker trials without citing new evidence, but our ﬁnd-
ings appear to support this change.
21
Target doses
Although a dose-related reduction in mortality and hospitalization
rates was shown in younger patients receiving carvedilol,
22 a recent
meta-analysis of 23 beta-blocker trials failed to show an association
between beta-blocker dose and survival beneﬁt in heart failure.
16
Our study was not designed to address the relationship of dose
beneﬁt; however, it does clearly raise the question of the achiev-
ability of currently recommended targets.
Predictors of tolerability
In agreement with other investigators, our ﬁndings show that
younger age and NYHA functional class II predicted patients’
ability to tolerate higher beta-blocker doses.
10,23 Beta-blocker pre-
treatment was a further predictor of tolerability in CIBIS-ELD,
which may be in favour of a slower approach to titration and is
in line with clinical observations that a quarter of the rec-
ommended beta-blocker dose is a hurdle to be overcome. A
body mass index .25 kg/m
2 being predictive of achieving higher
doses may be due to adverse effects probably being linked to
the volume of distribution, but is an observation that to our knowl-
edge has not been reported before.
Adverse effects
We expected that the vasodilatory effects of carvedilol might lead
to lower tolerability as a result of hypotension. In a review of selec-
tive vs. non-selective beta-blockers, the most frequent adverse
effects were reported to be worsening heart failure with bisopro-
lol, and hypotension and dizziness with carvedilol.
24 Our results do
not conﬁrm these ﬁndings. Anaemia as an adverse event was
observed more frequently in patients receiving carvedilol. These
results are in line with ﬁndings from the COMET trial.
25
Limitations
A correlation between tolerability to the target doses or titration
success and mortality cannot be established on the basis of our
data due to the short follow-up. Another limitation might be
that there is no recommended beta-blocker target dose for
patients with preserved LVEF. However, despite a lack of proven
reduction in mortality, there is an expert-based recommendation
of heart rate lowering using beta-blockers in diastolic heart
failure and for reasons of comparison, we used the same dose.
26
In addition, recent data from SENIORS suggest that beta-blockers
may possibly be effective in patients with LVEF .35%.
27 It may be
considered a limitation that only 25% of patients reached the
primary endpoint though a target of 50% was planned. However,
this should ﬁrst be seen as an unexpected outcome which
deserves consideration when speaking about the meaning of
target dose, and second, it is not a true limitation as the power
of the study was not reduced. Further, it was not mandatory for
CIBIS-ELD investigators to document reasons for titration failure.
Therefore, a blinded endpoint committee assessed the patients’
clinical data at the time of titration failure (for failures unrelated
to adverse events) and potential reasons for titration failure
were recorded where possible.
Conclusion and clinical
implications
In CIBIS-ELD, we found no difference in achieved doses and toler-
ability to target doses between bisoprolol and carvedilol in elderly
patients with heart failure, although the patterns of adverse effects
differed. With both agents, it appears that clinicians should follow
an individualized, slower, titration scheme. For patients with low
resting heart rates, physicians might prefer prescription of carvedi-
lol, and for patients with lung disease, the favourable beta-blocker
might be bisoprolol.
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